ID: ALA284745

Max Phase: Preclinical

Molecular Formula: C33H34N4O4

Molecular Weight: 550.66

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc([C@@H]2c3[nH]c4ccccc4c3C[C@@H]3C(=O)N([C@@H]4CCN(Cc5ccccc5)C4)CC(=O)N23)cc1OC

Standard InChI:  InChI=1S/C33H34N4O4/c1-40-28-13-12-22(16-29(28)41-2)32-31-25(24-10-6-7-11-26(24)34-31)17-27-33(39)36(20-30(38)37(27)32)23-14-15-35(19-23)18-21-8-4-3-5-9-21/h3-13,16,23,27,32,34H,14-15,17-20H2,1-2H3/t23-,27-,32-/m1/s1

Standard InChI Key:  HNZPKXUYPCLKGI-YYKZIPJASA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 550.66

Molecular Weight (Monoisotopic): 550.2580

AlogP: 4.14

#Rotatable Bonds: 6

Polar Surface Area: 78.11

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 7.81

CX LogP: 3.39

CX LogD: 2.84

Aromatic Rings: 4

Heavy Atoms: 41

QED Weighted: 0.39

Np Likeness Score: -0.53

References

1. Maw GN, Allerton CM, Gbekor E, Million WA..  (2003)  Design, synthesis and biological activity of beta-carboline-based type-5 phosphodiesterase inhibitors.,  13  (8): [PMID:12668004] [10.1016/s0960-894x(03)00159-8]

2. Beghyn TB, Charton J, Leroux F, Henninot A, Reboule I, Cos P, Maes L, Deprez B..  (2012)  Drug-to-genome-to-drug, step 2: reversing selectivity in a series of antiplasmodial compounds.,  55  (3): [PMID:22204607] [10.1021/jm201422e]

Source

Source(1):

• Scientific Literature